Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Edge Therapeutics brings in $18mm through RDO

Executive Summary

Edge Therapeutics Inc. netted $17.5mm through a registered direct offering of 1.8mm common shares at $10 (a 13% premium) to Satter Medical Technology Partners. The company will use the proceeds to further expand its pipeline and to fund pre-commercialization activities for lead compound EG1962, which is currently in Phase III for aneurysmal subarachnoid hemorrhage; results are expected later this year. EG1962 incorporates Edge's Precisa platform to create a polymer-based formulation of active ingredient nimodipine, delivered in a high concentration directly to the brain for sustained release in a single dose.
Deal Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Private Investment in Public Equity

Related Companies